Breaking News:

Abivax 2019 Financial Results and Operations Update

For more information, you can find our press release under the following link: https://abivax.gcs-web.com/system/files-encrypted/nasdaq_kms/news/2020/03/16/14-51-09/200316_Abivax_PR_FY%202019%20Financial%20Results_EN.pdf

Share Profile

Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.

  • ISIN code: FR0012333284
  • Symbol: ABVX
  • ICB Classification: Healthcare 4000/ Biotechnology 4573
  • Market: Euronext Paris-Compartment C
  • Type of Listing: continuous
  • Number of outstanding shares: 11 808 939 as of 30 September 2019
  • Indices: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
  • Eligible to French PEA PME

Analysts

LifeSci Capital Alpha Series:

Adam Evertts & David Sherman

Bryan, Garnier & Co:

Eric Le Berrigaud & Jean-Jacques Le Fur

goetzpartners securities:

Chris Redhead

Degroof Petercam:

Benoit Louage

Kepler Cheuvreux:

Damien Choplain

Portzamparc:

Christophe Dombu

Investor Contact

Chris Maggos LifeSci Advisors Chris@lifesciadvisors.com +41 79 367 6254